← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Sulfonylureas
gliquidone
A10BB08
Adult Dosing
- Initial: 15 mg to 30 mg daily before breakfast
- Maintenance: Up to 120 mg daily divided in 2-3 doses
- Maximum single dose: 60 mg
Pediatric Dosing
- Safety and efficacy not established in children
Indications
- Type 2 diabetes mellitus inadequately controlled by diet, exercise, and weight reduction
Mechanism of Action
- Second-generation sulfonylurea that stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels, reducing membrane depolarization and opening voltage-gated calcium channels
Contraindications
- Hypersensitivity to gliquidone or other sulfonylureas
- Type 1 diabetes mellitus
- Diabetic ketoacidosis or diabetic coma
- Severe hepatic impairment
- Severe renal impairment
- Pregnancy and lactation
Adverse Reactions
- Hypoglycemia
- Weight gain
- Gastrointestinal disturbances (nausea, vomiting, diarrhea)
- Transient visual disturbances
- Allergic skin reactions (pruritus, rash, urticaria)
- Rare: Hematological abnormalities (leukopenia, thrombocytopenia, hemolytic anemia)
Drug Interactions
- Potentiation of hypoglycemic effect with NSAIDs, salicylates, sulfonamides, coumarin derivatives, MAO inhibitors, beta-blockers, and alcohol
- Reduction of blood glucose-lowering efficacy with corticosteroids, thiazide diuretics, oral contraceptives, thyroid hormones, and sympathomimetics
Curated Content: Needs Vetting Before Put to Clinical Use